Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 9/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710481 | 0.88 | MAP4K1 (0.38) | MAP4K1METAP2METAP1PDE4APDE4C | |
| SCHEMBL1710223 | 0.80 | METAP2 (0.39) | METAP2METAP1PDE4APDE4CPDE4D | |
| SCHEMBL1710258 | 0.77 | MAP4K1 (0.53) | MAP4K1 | |
| SCHEMBL30167273 | 0.75 | METAP2 (0.43) | METAP2METAP1PDE4APDE4CPDE4D | |
| SCHEMBL249779 | 0.73 | METAP2 (0.64) | METAP2METAP1PDE4APDE4CPDE4D | |
| SCHEMBL25323447 | 0.72 | FABP1 (0.39) | PDE4APDE4CPDE4D | |
| SCHEMBL1710267 | 0.72 | METAP2 (0.42) | METAP2METAP1PIM1PIM3PIM2 | |
| SCHEMBL2944266 | 0.70 | METAP2 (0.40) | METAP2METAP1PDE4APDE4CPDE4D | |
| SCHEMBL3580521 | 0.70 | MEN1 (0.48) | METAP2 | |
| SCHEMBL19877811 | 0.70 | PDE4A (0.37) | PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759338-B2 | Heterocyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-8759338-B2 | Heterocyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2344473-B1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2344473-B1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2344473-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | MAP4K1 37/4885METAP2 3342/4885METAP1 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.